Pharma Focus Asia

Eyevance Pharmaceuticals Acquires FRESHKOTE® Lubricant Eye Drop Family of Products from Focus Laboratories

Wednesday, September 12, 2018

Eyevance Pharmaceuticals, LLC, a Fort Worth-based pharmaceutical company committed to developing and commercializing innovative and impactful ophthalmic products, today announced the acquisition of FRESHKOTE® - a family of lubricant eye drops from Focus Laboratories, Inc. Under the terms of the agreement, Eyevance acquired FRESHKOTE® and all its formulations, including the unique, state-of-the-art preservative-free multi-dose bottle and single-unit vials to market and commercialize worldwide.

New FRESHKOTE® PF is designed to support the integrity of all three layers of the eye's tear film, offering dry eye patient's relief from their symptoms. FRESHKOTE® PF combats evaporation on the ocular surface with a patented polymer blend formulated to mimic the lipid layer of the tear film. Notably, due to its non-irritating profile, FRESHKOTE® PF is safe for contact lens wearers and can be used on an as-needed basis. A non-prescription product, new FRESHKOTE® PF is available in 10-mL multi-dose bottles or boxes of 30 single-unit vials. FRESHKOTE® PF can be professionally recommended to patients and sold behind the pharmacy counter.

"The acquisition of the FRESHKOTE® franchise represents an important business milestone for Eyevance, which is actively building a portfolio of impactful and innovative eye care products, focused on the anterior segment of the eye," commented Jerry St. Peter, Chief Executive Officer and Director, Eyevance. "With the introduction of FRESHKOTE® PF, Eyevance is the first and only company to now offer an eye lubricant product line that is exclusively preservative free, available in both a multi-dose bottle and single-unit vials."

"The tear market is oversaturated with preserved formulations, therefore, FRESHKOTE® PF is a welcomed, vanguard addition for patients with dry eye," St. Peter stated.

"I've been recommending original FRESHKOTE® to my patients for about a decade now," said Paul M. Karpecki, OD, FAAO. "With the introduction of FRESHKOTE® PF, my patients can get all the benefits of FRESHKOTE® without any preservatives. FRESHKOTE® PF's high oncotic pressure stabilizes the tear film, allowing the integrity of the epithelium to be re-established, a unique mechanism that's highly appealing from a clinical perspective. My patients typically respond very well to the drops, making it a go-to product in my dry eye armamentarium."

"Following our new reformulation and improvement of FRESHKOTE®, we are excited to hand off this asset to an emerging ophthalmic-focused company," said Patrick Witham, Director, Focus Laboratories, Inc. "This divestiture provides the opportunity for Focus to further concentrate its efforts on the discovery and development of new innovative therapies in ocular medicine."

Eyevance's acquisition of the FRESHKOTE® family of products follows the announcement of an exclusive Licensing Agreement with Nicox Ophthalmics, Inc. for prescription-only ZERVIATE™ (cetirizine ophthalmic solution) 0.24% for the treatment of ocular itching associated with allergic conjunctivitis. Eyevance plans to launch ZERVIATE™ in early 2019.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024